Eli Lilly and Company (NYSE: LLY) — Stock Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products across the United States, Europe, China, Japan, and other international markets. Its business spans four core therapeutic areas woven through its portfolio: cardiometabolic health, oncology, immunology, and neuroscience. Cardiometabolic products include a broad insulin franchise under the Humalog and Humulin families alongside Jardiance, Mounjaro, Trulicity, and Zepbound, which addresses obesity. The oncology range covers treatments for gastric, colorectal, head and neck, and breast cancers as well as lymphoma and non-small cell lung cancer, through products such as Cyramza, Erbitux, Verzenio, and Retevmo, among others.

The immunology portfolio targets conditions including rheumatoid arthritis, atopic dermatitis, plaque psoriasis, psoriatic arthritis, and ulcerative colitis through Olumiant, Taltz, Ebglyss, and Omvoh, while the neuroscience segment offers Emgality for migraine prevention and episodic cluster headache and Kisubla for symptomatic Alzheimer's disease. The company operates under collaborations with Boehringer Ingelheim for the Jardiance family, F. Hoffmann-La Roche and Genentech for lebrikizumab, and holds license agreements with Almirall for Ebglyss and Chugai Pharmaceutical for orforglipron. Founded in 1876, Eli Lilly is headquartered in Indianapolis, Indiana.